Literature DB >> 11549623

Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation.

C A Stratakis1, L S Kirschner, J A Carney.   

Abstract

Carney complex is a multiple neoplasia syndrome featuring cardiac, endocrine, cutaneous, and neural tumors, as well as a variety of pigmented lesions of the skin and mucosae. Carney complex is inherited as an autosomal dominant trait and may simultaneously involve multiple endocrine glands, as in the classic multiple endocrine neoplasia syndromes 1 and 2. Carney complex also has some similarities to McCuneAlbright syndrome, a sporadic condition that is also characterized by multiple endocrine and nonendocrine tumors. Carney complex shares skin abnormalities and some nonendocrine tumors with the lentiginoses and certain of the hamartomatoses, particularly Peutz-Jeghers syndrome, with which it shares mucosal lentiginosis and an unusual gonadal tumor, large-cell calcifying Sertoli cell tumor. Careful clinical analysis has enabled positional cloning efforts to identify two chromosomal loci harboring potential candidate genes for Carney complex. Most recently, at the 17q22-24 locus, the tumor suppressor gene PRKAR1A, coding for the type 1alpha regulatory subunit of PKA, was found to be mutated in approximately half of the known Carney complex kindreds. PRKAR1A acts a classic tumor suppressor gene as demonstrated by loss of heterozygosity at the 17q22-24 locus in tumors associated with the complex. The second locus, at chromosome 2p16, to which most (but not all) of the remaining kindreds map, is also involved in the molecular pathogenesis of Carney complex tumors, as demonstrated by multiple genetic changes at this locus, including loss of heterozygosity and copy number gain. Despite the known genetic heterogeneity in the disease, clinical analysis has not detected any corresponding phenotypic differences between patients with PRKAR1A mutations and those without. This article summarizes the clinical manifestations of Carney complex from a worldwide collection of affected patients and also presents revised diagnostic criteria for Carney complex. In light of the recent identification of mutations in the PRKAR1A gene, an estimate of penetrance and recommendations for genetic screening are provided.

Entities:  

Mesh:

Year:  2001        PMID: 11549623     DOI: 10.1210/jcem.86.9.7903

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  179 in total

Review 1.  PRKAR1A and the evolution of pituitary tumors.

Authors:  Lawrence S Kirschner
Journal:  Mol Cell Endocrinol       Date:  2010-05-06       Impact factor: 4.102

2.  Children with Cushing's syndrome: Primary Pigmented Nodular Adrenocortical Disease should always be suspected.

Authors:  Renata Marques Gonçalves da Silva; Emília Pinto; Suzan M Goldman; Cássio Andreoni; Teresa C Vieira; Julio Abucham
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

3.  Virilizing ovarian stromal tumor in a young woman with Carney complex.

Authors:  J Aidan Carney; Constantine A Stratakis
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

Review 4.  Novel genetic mutation in the background of Carney complex.

Authors:  Csaba Halászlaki; István Takács; Henriett Butz; Attila Patócs; Péter Lakatos
Journal:  Pathol Oncol Res       Date:  2012-04       Impact factor: 3.201

Review 5.  Protein kinase A defects and cortisol-producing adrenal tumors.

Authors:  Mihail Zilbermint; Constantine A Stratakis
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-06       Impact factor: 3.243

Review 6.  Genetics of Cushing's Syndrome.

Authors:  Laura C Hernández-Ramírez; Constantine A Stratakis
Journal:  Endocrinol Metab Clin North Am       Date:  2018-06       Impact factor: 4.741

7.  Novel Mutation in PRKAR1A in Carney Complex.

Authors:  Ko Un Park; Hyun-Sook Kim; Seung Kwan Lee; Woon-Won Jung; Yong-Koo Park
Journal:  Korean J Pathol       Date:  2012-12-26

8.  Blue Nevi of the Ocular Surface: Clinical Characteristics, Pathologic Features, and Clinical Course.

Authors:  Ibrahim Sayed-Ahmed; Juan Carlos Murillo; Pedro Monsalve; Jan Paul Ulloa; Maria P Fernandez; James Wong; George Elgart; Anat Galor; Sander R Dubovy; Carol L Karp
Journal:  Ophthalmology       Date:  2018-03-15       Impact factor: 12.079

9.  Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production.

Authors:  Georgette N Jones; Chhavy Tep; William H Towns; Georgeta Mihai; Ian D Tonks; Graham F Kay; Petra M Schmalbrock; Anat O Stemmer-Rachamimov; Sung Ok Yoon; Lawrence S Kirschner
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

10.  Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes.

Authors:  Jérôme Bertherat; Anélia Horvath; Lionel Groussin; Sophie Grabar; Sosipatros Boikos; Laure Cazabat; Rosella Libe; Fernande René-Corail; Sotirios Stergiopoulos; Isabelle Bourdeau; Thalia Bei; Eric Clauser; Alain Calender; Lawrence S Kirschner; Xavier Bertagna; J Aidan Carney; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2009-03-17       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.